Operating Income (Loss) in USD of Kairos Pharma, LTD. from Q3 2023 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Kairos Pharma, LTD. quarterly/annual Operating Income (Loss) history and change rate from Q3 2023 to Q3 2025.
  • Kairos Pharma, LTD. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$1,435,000.000, a 275% decline year-over-year.
  • Kairos Pharma, LTD. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$5,608,000.000.
  • Kairos Pharma, LTD. annual Operating Income (Loss) for 2024 was -$2,343,000.000, a 36.7% decline from 2023.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Kairos Pharma, LTD. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$5,608,000 -$1,435,000 -$1,052,000 -2.7% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$4,556,000 -$1,456,000 -$1,234,000 -5.6% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025
Q1 2025 -$3,322,000 -$1,266,000 -$979,000 -3.4% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025
Q4 2024 -$2,343,000 -$1,451,000 01 Oct 2024 31 Dec 2024 10-K 15 Apr 2025
Q3 2024 -$383,000 -$96,000 -33.4% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$222,000 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025
Q1 2024 -$287,000 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025
Q3 2023 -$287,000 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024

Kairos Pharma, LTD. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$2,343,000 -$629,000 -36.7% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025
2023 -$1,714,000 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025
* An asterisk sign (*) next to the value indicates that the value is likely invalid.